A Phase 1b, Double-blinded, Placebo-controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Subjects With Multiple Sclerosis (ms)

Trial Profile

A Phase 1b, Double-blinded, Placebo-controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Subjects With Multiple Sclerosis (ms)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs PF 6342674 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Jan 2016 Planned End Date changed from 1 Jan 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
    • 12 Jan 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
    • 02 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top